Revolution Medicines (RVMD)
(Delayed Data from NSDQ)
$35.33 USD
-0.26 (-0.73%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $35.19 -0.14 (-0.40%) 5:06 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Revolution Medicines, Inc. [RVMD]
Reports for Purchase
Showing records 1 - 20 ( 37 total )
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Several Catalysts Expected in 2024; 2023 Financials; Raising PT to $44
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Rolling into 2024; RMC-6236 Expansion Cohorts, Data Updates
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Not Working? Try the ''On'' Switch; Initiating at OUTPERFORM with a $41 PT
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
EQRx Acquisition Completed; 3Q23 Financials; Modulating PT to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Triple Meeting and ESMO Takeaways; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Significant Near-Term Catalysts; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Cash Injection Through EQRx Acquisition; ESMO Data Pending; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Multiple Presentations at AACR Conference; 4Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Sanofi Hands Back Rights to RMC-4630; Competitive Landscape Update; Modulating PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
CodeBreak 101c Positive Early Data; 2Q22 Financials; Modulating PT to $37
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
A Plethora of RAS(ON) Presentations at AACR; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
2021 Financial Results Reported; Raising PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R